Featured Research

from universities, journals, and other organizations

Combination Vaccine Produces Lower Immune Response Than Vaccines Administered Separately

Date:
April 21, 2005
Source:
Journal Of The American Medical Association
Summary:
A combination vaccine developed to reduce the number of vaccines infants receive appears to provide less immunity than the vaccines administered individually, according to a study in the April 13 issue of JAMA.

CHICAGO — A combination vaccine developed to reduce the number of vaccines infants receive appears to provide less immunity than the vaccines administered individually, according to a study in the April 13 issue of JAMA.

The development of immunogenic vaccines against major diseases of childhood has dramatically decreased the rates of invasive disease, according to background information in the article. Since the introduction of a monovalent serogroup C meningococcal glycoconjugate vaccine (MenC) into the United Kingdom routine immunization schedule in November 1999, group C meningococcal disease has decreased by 87 percent in the ages targeted for vaccination, with estimated vaccine efficacy of 90 percent. Within 2 years of the introduction of a 7-valent pneumococcal glycoconjugate vaccine into the recommended infant schedule in the United States, there was a 69 percent reduction in culture-positive invasive pneumococcal disease in children younger than 2 years.

The advent of these efficacious and safe vaccines has increased pressure on crowded infant immunization schedules. Infants in the United States receive up to 20 separate vaccine injections over 5 immunization encounters at ages 2, 4, 6, 12, and 18 months to protect against disease due to hepatitis B, diphtheria, tetanus, pertussis, polio, measles, mumps, rubella, varicella, H influenzae type b, and pneumococcus. The inclusion of MenC would add a further 3 to 4 doses to the U.S. regimen. The development of combination vaccines has become a priority. The combining of pneumococcal and meningococcal conjugate vaccines has the potential to spare U.S. infants up to 4 extra injections by age 18 months and to decrease parental and clinician concerns about the number of vaccinations in early childhood.

Jim P. Buttery, F.R.A.C.P., formerly of the University of Oxford, Churchill Hospital, Headington, Oxford, U.K., and colleagues conducted a study to determine the immunogenicity and safety of a combination 9-valent pneumococcal-group C meningococcal conjugate candidate vaccine (Pnc9-MenC). The phase 2 randomized controlled trial was conducted from August 2000 to January 2002 and enrolled 240 healthy infants aged 7 to 11 weeks from 2 U.K. centers, with home follow-up visits at ages 2, 3, 4, and 5 months. Infants received Pnc9-MenC (n = 120) or monovalent group C meningococcal conjugate vaccine (MenC) (n = 120) administered in addition to routine immunizations (diphtheria and tetanus toxoids and whole-cell pertussis [DTwP], Haemophilus influenzae type b (Hib) polyribosylribitol phosphate-tetanus toxoid protein conjugate, oral polio vaccine).

The researchers found: "Pnc9-MenC combination vaccine administered to infants at ages 2, 3, and 4 months demonstrated reduced group C meningococcal immunogenicity compared with MenC vaccine. The immunogenicity of concomitantly administered Hib and DTwP vaccines was also diminished. The Pnc9-MenC vaccine was safe and immunogenic for all contained pneumococcal serotypes."

"These results highlight the unpredictability of immune responses to individual vaccine antigens after incorporating multiple antigens into combination vaccines and underline the importance of assessing the immunogenicity of all coadministered vaccine antigens in prelicensure trials. The Pnc9-MenC vaccine as tested may not be a suitable replacement for individual MenC or pneumococcal glycoconjugate vaccines," the authors conclude.

(JAMA. 2005;293:1751-1758. Available post-embargo at jama.com)

Editor's Note: This study was funded by Wyeth Vaccines. For financial disclosure information, please see the JAMA article. Dr. Buttery is now with the Department of General Medicine, Murdoch Children's Research Institute, University of Melbourne Department of Paediatrics, Royal Children's Hospital, Melbourne, Australia.


Story Source:

The above story is based on materials provided by Journal Of The American Medical Association. Note: Materials may be edited for content and length.


Cite This Page:

Journal Of The American Medical Association. "Combination Vaccine Produces Lower Immune Response Than Vaccines Administered Separately." ScienceDaily. ScienceDaily, 21 April 2005. <www.sciencedaily.com/releases/2005/04/050420091653.htm>.
Journal Of The American Medical Association. (2005, April 21). Combination Vaccine Produces Lower Immune Response Than Vaccines Administered Separately. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2005/04/050420091653.htm
Journal Of The American Medical Association. "Combination Vaccine Produces Lower Immune Response Than Vaccines Administered Separately." ScienceDaily. www.sciencedaily.com/releases/2005/04/050420091653.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins